Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Claridgeon Jun 13, 2019 2:20pm
70 Views
Post# 29823339

RE:RE:When Does Ph 2 First Patient Get Treated?

RE:RE:When Does Ph 2 First Patient Get Treated?Mid-2015, ICON signed a deal with IBM to improve its clinical trial enrollment process because ICON was rating extremely low on its ability to recruit and enroll patients in clinical trials.

 

  • Dublin, Ireland

ICON applies IBM Watson clinical trial matching to oncology clinical trials

ICON and IBM to Revolutionise Clinical Trial Feasibility, Patient Recruitment and Study Start-up Timelines

ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it is working with IBM (NYSE: IBM) to help reduce the time and costs of drug development, while also offering patients enhanced quality of care by connecting them to relevant clinical trials. ICON will tap Watson's cognitive computing power to help automate the cumbersome process of identifying patients who meet the criteria for a clinical trial, and to analyse protocols to assess trial feasibility and identify optimal trial sites.



The cost and time involved in clinical trials is considerable. More than $1.3B is spent on patient recruitment by drug developers each year and yet fewer than 5% of cancer patients participate in a clinical trial. It also typically takes 6-12 months to start up a global phase III drug trial and another 12 months to enroll the required number of patients.   

Commenting on the announcement, ICON’s Chief Operating Officer, Dr. Steve Cutler, said: “Recruiting the required number of patients for clinical trials is a constant challenge for our customers and can represent more than 30% of total study costs. By applying IBM Watson to our clinical trials, we have the potential to revolutionise clinical trial feasibility, patient recruitment and study start-up timelines which will help our customers take significant time and cost from their development programmes. Together with IBM, we are also providing a better and faster way to connect patients with clinical trials that are most relevant to them.


4 years later, we see this on ICON's website:


5 June 2019

Technology the Key for Improving Trial Efficiencies & Retention



Learn how the use of technology has become ubiquitous in clinical trials as the industry looks to streamline and improve processes.


9 May 2019

ICON Launches New Patient Engagement Platform to Support Improved Patient Experience and Enrolment in Clinical Trials

Increasing visibility of potential study participants to sites and sponsors


There are other AI softwares trying to shorten the time to enroll patients:


Streamlining Clinical Trials with AI - Saama Technologies

April 4, 2019

A clinical trial involves a set of complex processes, which include writing the protocol, recruiting patients, conducting the study, and culminating in bringing the drug to market. There are many stakeholders involved, in different capacities, to carry out these processes, ensure adherence to regulations, and keep the trial on track.

Here are some of the most important areas of a clinical trial that require constant attention and have a serious impact on the outcome of the trial:

Clinical Study Spend: This is the most critical aspect of a clinical trial that needs to be always monitored. Almost 80% of clinical trials go over budget, for one reason or another, and trial managers are often under pressure to keep the costs down.

Clinical Study Timelines: Extended timelines are often treated as the norm rather than an anomaly during clinical trials. Many factors contribute directly to these extended timelines, some of which are delays and challenges in patient recruitment, site selection, and investigator analysis. Extended timelines directly impact the cost, therefore knowing which trial processes are lagging is essential for a trial manager.

 

 

Bullboard Posts